Drug intelligence / Profile preview

Carilizumab

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Carilizumab is a monoclonal antibody that functions as a Programmed Death-1 (PD-1) inhibitor. It is currently under investigation for the treatment of advanced dMMR gastric cancer, often in combination with other therapeutic agents such as apatinib. By blocking the PD-1 pathway, Carilizumab aims to enhance the body's anti-tumor immune response, allowing the immune system to better recognize and attack cancer cells. The drug is being developed by entities including The First Affiliated Hospital of Anhui Medical University.

Other names: karillicumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on Carilizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carilizumab.

Explore the full profile